Transfusion reactions associated with COVID-19 convalescent plasma therapy for SARS-CoV-2

Keyphrases

• COVID-19 100%
• Transfusion Reaction 100%
• Convalescent Plasma Therapy 100%
• COVID-19 Convalescent Plasma 100%
• Transfusion 66%
• Convalescent Plasma 66%
• Clinical Parameters 33%
• Risk Factors 16%
• Statistical Analysis 16%
• Low Risk 16%
• Serious Adverse Events 16%
• Patient Demographics 16%
• Therapeutic Potential 16%
• Disease Severity 16%
• Adult Patients 16%
• Decreased Risk 16%
• Health Systems 16%
• Clinical Significance 16%
• U.S. Food 16%
• Reduced Mortality 16%
• Age Groups 16%
• Retrospective Analysis 16%
• Mount Sinai 16%
• Laboratory Parameters 16%
• Sequential Organ Failure Assessment 16%
• Reaction Parameters 16%
• Expanded Access 16%
• Investigational New Drug 16%
• Adult Inpatients 16%
• Clinical Risk 16%
• Reaction Types 16%
• Severely Ill Patients 16%
• Mayo Clinic 16%
• Blood Group B 16%
• Non-haemolytic 16%
• ABO Blood Group 16%
• ABO Group 16%
• Group Sequential Design 16%
• Parameter Factor 16%
• Transfusion-associated Circulatory Overload 16%

Medicine and Dentistry

• Severe Acute Respiratory Syndrome Coronavirus 2 100%
• COVID-19 100%
• Blood Transfusion Reaction 100%
• Adverse Event 16%
• Disease Severity 16%
• Coronavirinae 16%
• Health System 16%
• Clinical Significance 16%
• SOFA Score 16%
• Blood Group B 16%
• Plasma Transfusion 16%
• Blood Group ABO System 16%

Nursing and Health Professions

• Severe Acute Respiratory Syndrome 100%
• Blood Transfusion Reaction 100%
• Adverse Event 16%
• Disease Severity 16%
• Hospital 16%
• Food and Drug Administration 16%
• Sequential Organ Failure Assessment Score 16%
• Plasma Transfusion 16%
• Blood Group ABO System 16%
• Blood Group B 16%